Annual report of the Committee on Gynecologic Oncology, the Japan Society of Obstetrics and Gynecology: Annual Patient Report for 2018 and Annual Treatment Report for 2013

Abstract

To provide information including the trend of gynecological malignancies in Japan, we hereby present the Annual Patient Report for 2018 and the Annual Treatment Report for 2013, on the outcomes of patients who started treatment in 2013. The Japan Society of Obstetrics and Gynecology maintains an annual tumor registry, where information on gynecological malignancies from various participating institutions is gathered. The data of patients whose treatment with gynecologic malignancies was initiated in 2018 were analyzed retrospectively. Survival of the patients who started treatment with cervical, endometrial, and ovarian cancer in 2013 was analyzed by using the Kaplan-Meier, log-rank, and Wilcoxson tests. Treatment was initiated in 2018 for 7304 patients with cervical cancer; 11 230 with endometrial cancer; 7031 with ovarian, tubal, and peritoneal cancer; 2072 with ovarian borderline tumors; and with the others (222 vulvar cancer, 159 vaginal cancer, 413 uterine sarcoma, 54 uterine adenosarcoma, and 135 trophoblastic diseases). This clinicopathological information was summarized as the Patient Annual Report. The 5-year survival rates of the patients with cervical cancer were 93.1%, 75.9%, 59.1%, and 31.2% for Stages I, II, III, and IV, respectively. The 5-year survival rates for the patients with endometrial cancer were 94.1%, 89.2%, 73.6%, and 25.8% for Stages I, II, III, and IV, respectively. The 5-year survival rates for the patients with ovarian cancer (surface epithelial-stromal tumors) were 89.7%, 76.8%, 49.1%, and 32.4% for Stages I, II, III, and IV, respectively. The annual report is important to provide knowledge on gynecological malignancy trends in Japan.

Annual report of the committee on gynecologic oncology, the Japan Society of Obstetrics and Gynecology: Annual patient report for 2019 and annual treatment report for 2014

“…The 5‐year survival rate was for cervical, endometrial, and ovarian cancers (all stages) were 70.9%, 77.9%, and 59.6%, respectively. Compared to the 2013 treatment outcomes (cervical cancer: 71.5%; endometrial cancer: 78.1%; and ovarian cancer: 59.4%), 3 there was no notable change in the prognosis for gynecologic cancers in Japan. The American Cancer Society reported the 5‐year survival rate (all SEER stages combined) of 66%, 84%, and 48% for cervical, endometrial, and ovarian cancers, respectively, based on patients diagnosed with those cancers between 2010 and 2017 6 .…”

“…These findings suggest that the increase was not only due to an increase in the number of participating institutions (2018: 449, 2019: 468 institutions), but also due to the increasing prevalence of registration for gynecological malignancies in Japan. There was no change in the respective percentages of registered patients with stages I‐IV cervical, endometrial, ovarian, tubal, and peritoneal cancers in 2019, compared to those in the 2018 Annual Patient Report 3 …”

“…This study investigated the 2019 gynecological malignancy trends in Japan and analyzed the prognosis of gynecological malignancies for treatment was initiated in 2014, as the tumor registries project of the JSOG. A comparison of the numbers of patients with gynecological malignancies in 2018 and 2019 revealed an increase in the number of registered patients for all gynecological malignancies, namely, cervical cancer (2018: 7304, 2019: 7983 patients), endometrial cancer (2018: 11 280, 2019: 12631 patients), and ovarian cancer (2018: 7031, 2019: 7737 patients) 3 . These findings suggest that the increase was not only due to an increase in the number of participating institutions (2018: 449, 2019: 468 institutions), but also due to the increasing prevalence of registration for gynecological malignancies in Japan.…”

Prognostic value of tumor volume reduction during radiotherapy in patients with locally advanced cervical cancer in different risk groups

“…LACC is a highly heterogeneous disease, and even among patients exhibiting equivalent TVR levels, there also may be pronounced residual disease-related heterogeneity. The FIGO stage is directly related to prognosis and guides the strati cation of patients to different treatment regimens [11,12]. Wagner et al [17] retrospectively analyzed 18,649 CC patients from the SEER database and found that TV was an independent prognostic factor across all FIGO stages.…”

“…There also remains pronounced disease-related heterogeneity even among patients exhibiting equivalent TVR levels. The reported 5-year overall survival (OS) rates of CC patients with International Federation of Gynecology and Obstetrics (FIGO) stages II, III, and IV disease are 65-69%, 40-43%, and 15-20% respectively [11,12]. Other parameters related to treatment outcomes in CC patients include age, tumor size, and levels of different tumor markers [13,14].…”